Anti-Pentatrichomonas hominis activity of newly synthesized benzimidazole derivatives - in vitro studies

• Autorzy: Chomicz L , Padzik M. , Laudy A.E. , Kozlowska M. , Pietruczuk A. , Piekarczyk J. , Godineau N. , Oledzka G. , Kazimierczuk Z.
• Języki publikacji: EN

Abstrakty

EN

Pentatrichomonas hominis, a parasitic protozoan often detected in human diarrheic stools, is the cause of severe morbidity in newborns and children, particularly in tropical zones. The flagellate is resistant to many disinfectants and anti-protozoan drugs. Therefore in this study we have synthesized three novel 4,5,6,7-tetrabromobenzimidazole (TBBI) derivatives carrying a polyfluoroalkyl substituent in position 2 of the benzimidazole scaffold, namely 2-trifluoromethyl-TBBI (CF3-TBBI), 2-nonafluorobutyl-TBBI (C4F9-TBBI), and 2-nonadecafluorononyl-TBBI (C9F19-TBBI), that next we tested for their in vitro activity against P. hominis.Widely applied anti-protozoal drug, metronidazole as a reference was used. All the investigated agents were added to 24 h P. hominis cultures; each of them was administered at three different concentrations. Number of the moving trichomonads was determined and compared with the control cultures. Different anti-trichomonal activity occurred depending on a kind of compound and its concentration. C4F9-TBBI was the most effective TBBI derivative tested: the agent, at the highest concentration 24.2 μg/ml, after 72 h reduced the number of viable trichomonads to 44.3%; C9F19-TBBI, at the concentration 24 μg/ml reduced the number of the flagellates to 58.5%. Paradoxically, metronidazole after the same time given at the highest concentration increased trophozoite counts by 464.6% in comparison with the control cultures (100%).

Słowa kluczowe

EN

parasitic protozoan; Pentatrichomonas hominis; benzimidazole derivative; metronidazole

• Wydawca: -
• Czasopismo: Acta Parasitologica
• Rocznik: 2009
• Tom: 54
• Numer: 2
• Opis fizyczny: p.165-171,fig.,ref.

Twórcy

autor

Chomicz L

• Medical University of Warsaw, 73 Nowogrodzka Street, 02-018 Warsaw, Poland

autor

Padzik M.

autor

Laudy A.E.

autor

Kozlowska M.

autor

Pietruczuk A.

autor

Piekarczyk J.

autor

Godineau N.

autor

Oledzka G.

autor

Kazimierczuk Z.

Bibliografia

• Al-Dabagh M.A., Shafiq M.A. 1970. Pathogenicity of Trichomonas hominis to splenectomized rats. Transactions of the Royal Society of Tropical Medicine and Hygiene, 64, 826–828. DOI:10.1016/0035-9203(70)90100-8.
• Alunni Bistocchi G., De Meo G., Pedini M., Ricci A., Bastianini L., Sposini T., Sbaraglia G., Jacquignon P. 1986. New heterocyclic derivatives of benzimidazole with germicidal activity. III. Synthesis and activity of derivatives of (formyl-5′-furyl-2′)-2 benzimidazole with different substitutions at position 5. Farmaco-edizione Scientifica, 41, 970–983.
• Andrzejewska M., Pagano M.A., Meggio F., Brunati A.M., Kazimierczuk Z. 2003. Polyhalogenobenzimidazoles: Synthesis and their inhibitory activity against casein kinases. Bioorganic & Medical Chemistry, 11, 3997–4002. DOI: 10.1016/S0968-0896(03)00403-6.
• Andrzejewska M., Yépez-Mulia L., Cedillo-Rivera R., Tapia A., Vilpo L., Vilpo J., Kazimierczuk Z. 2002. Synthesis, antiprotozoal and anticancer activity of substituted 2-trifluoromethyland 2-pentafluoroethylbenzimidazoles. European Journal of Medicinal Chemistry, 37, 973–978. DOI: 10.1016/S0223-5234(02)01421-6.
• Blaha C., Duchêne M., Aspöck H., Walochnik J. 2006. In vitro activity of hexadecylphosphocholine (miltefosine) against metro-nidazole-resistant and susceptible strains of Trichomonas vaginalis. Journal of Antimicrobial Chemotherapy, 57, 273–278. DOI: 10.1093/jac/dki417.
• Borchardt K.A., Li Z., Zhang M.Z., Shing H. 1996. An in vitro metronidazole susceptibility test for trichomoniasis using the InPouch TV test. Genitourinary Medicine, 72, 132–135.
• Büchel K.H. 1970. Inhibitors of photosynthesis. V. Herbicidal trifluoromethyl-benzimidazoles. Zeitschrift für Naturforschung, 25b, 934–944.
• Cedillo-Rivera R., Chávez B., González-Robles A., Tapia A., Yépez-Mulia L. 2002. In vitro effect of nitazoxanide against Entamoeba histolytica, Giardia intestinalis and Trichomonas vaginalis trophozoites. Journal of Eukaryotic Microbiology, 49, 201–208. DOI: 10.1368/1066-5234(2002)049[0201:IVECONA]2.0.CO;2.
• Cedillo-Rivera R., Muñoz O. 1992. In-vitro susceptibility of Giardia lamblia to albendazole, mebendazole and other chemotherapeutic agents. Journal of Medical Microbiology, 37, 221–224.
• Chomicz L., Żebrowska J., Piekarczyk J., Starościak B., Myjak P., Walski M., Kazimierczuk Z. 2005. In vitro studies on susceptibility of Acanthamoeba castellanii to selected chemical agents. Acta Parasitologica, 50, 25–31.
• Chomicz L., Żebrowska J., Zawadzki P., Myjak P., Perkowski K., Rebandel H., Kazimierczuk Z. 2004. Badania nad wrażliwością Trichomonas hominis na czynniki abiotyczne. I. Wstępna ocena przeżywalności wiciowców w wybranych mediach w warunkach in vitro. Wiadomości Parazytologiczne, 50, 405–409.
• Chunge R.N., Simwa J.M., Karumba P.N., Kenya P.R., Kinoti S.N., Mattunga J., Nagelkerke N. 1992. Comparative aetiology of childhood diarrhoea in Kakamega and Kiambu Districts, Kenya. East African Medical Journal, 69, 437–441.
• Crucitti T., Abdellati S., Ross D.A., Changalucha J., van Dyck E., Buve A. 2004. Detection of Pentatrichomonas hominis DNA in biological specimens by PCR. Letters in Applied Microbiology, 38, 510–516. DOI: 10.1111/j.1472-765X.2004.01528.x.
• Górska A., Chomicz L., Żebrowska J., Myjak P., Augustynowicz-Kopeć E., Zwolska Z., Piekarczyk J., Rebandel H., Kazimierczuk Z. 2006. Synthesis and antimycobacterial and antiprotozoal activities of some novel nitrobenzylated heterocycles. Zeitschrift für Naturforschung, 61b, 101–107.
• Guillaume V. 2007. Biologie Medicale Pratique. Parasitologie. De Boek & Lacier, Bruxelles, Belgie, 183 pp.
• Honigberg B.M. 1990. Trichomonad found outside the urogenital tract of humans. In: (Ed. B.M. Honigberg) Trichomonads Parasitic in Humans. Springer-Verlag, New York, 342–393.
• Ings R.M., McFadzean J.A., Ormerod W.E. 1974. The mode of action of metronidazole in Trichomonas vaginalis and other microorganisms. Biochemical Pharmacology, 23, 1421–1429. DOI: 10.1016/0006-2952(74)90362-1.
• Jacobsen E.B., Friis-Moller A., Friis J. 1987. Trichomonas species in a subhepatic abscess. European Journal of Clinical Microbiology and Infectious Diseases, 6, 296–297. DOI: 10.1007/BF02017616.
• Jongwutiwes S., Silachamroon U., Putaporntip C. 2000. Pentatrichomonas hominis in empyema thoracis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 94, 185–186. DOI: 10.1016/S0035-9203(00)90270-0.
• Kasten J.M. 1999. Clindamycin, metronidazole and chloramphenicol. Mayo Clinic Proceedings, 74, 825–833. DOI: 10.4065/74.8.825.
• Kazimierczuk Z., Upcroft J.A., Upcroft P., Górska A., Starościak B., Laudy A. 2002. Synthesis, antiprotozoal and antibacterial activity of nitro- and halogeno-substituted benzimidazole derivatives. Acta Biochimica Polonica, 49, 185–195.
• Kopańska K., Najda A., Żebrowska J., Chomicz L., Piekarczyk J., Myjak P., Brenner M. 2004. Synthesis and activity of 1H-benzimidazole and 1H-benzotriazole derivatives as inhibitors of Acanthamoeba castellanii. Bioorganic & Medicinal Chemistry, 12, 2617–2624. DOI: 10.1016/j.bmc.2004.03.022.
• Kulda J. 1999. Trichomonads, hydrogenosomes and drug resistance. International Journal for Parasitology, 29, 199–212. DOI: 10.1016/S0020-7519(98)00155-6.
• Land K.M., Johnson P.J. 1999. Molecular basis of metronidazole resistance in pathogenic bacteria and protozoa. Drug Resistance Updates, 2, 289–294. DOI: 10.1054/drup.1999.0104.
• Mancilla-Ramirez J., Gonzalez-Yunes R. 1989. Diarrhea associated with Trichomonas hominis in a newborn infant. Boletin Medico del Hospital Infantil de Mexico, 46, 623–625.
• Meingassner J.G., Thurner J. 1979. Strain of Trichomonas vaginalis resistant to metronidazole and other 5-nitroimidazoles. Antimicrobial Agents and Chemotherapy, 15, 254–257.
• Meri T., Jokiranta T.S., Suhonen L., Meri S. 2000. Resistance of Trichomonas vaginalis to metronidazole: report of the first three cases from Finland and optimization of in vitro susceptibility testing under various oxygen concentrations. Journal of Clinical Microbiology, 38, 763–767.
• Munoz E., Castella J., Gutierrez J.F. 1998. In vivo and in vitro sensitivity of Trichomonas gallinae to some nitroimidazole drugs. Veterinary Parasitology, 78, 239–246. DOI: 10.1016/S0304-4017(98)00164-2.
• Myjak P. 1974. The use of solid medium cultures for the removal of bacteria and fungi from Entamoeba histolytica strains. Bulletin of the Institute of Maritime and Tropical Medicine in Gdynia, 25, 113–120.
• Narcisi E.M., Secor W.E. 1996. In vitro effect of tinidazole and furazolidone on metronidazole-resistant Trichomonas vaginalis. Antimicrobial Agents and Chemotherapy, 40, 1121–1125.
• Petersen K. 1988. Protozoological stool examinations from 1980 to 1985 in the East German district of Rostock. Angewandte Parasitologie, 29, 3–10.
• Rasoloson D., Tomková E., Cammack R., Kulda J., Tachezy J. 2001. Metronidazole-resistant strains of Trichomonas vaginalis display increased susceptibility to oxygen. Parasitology, 123, 45–56. DOI: 10.1017/S0031182001008022.
• Reinthalter F.F., Mascher F., Klem G., Sixl W. 1988. A survey of gastrointestinal parasites in Ogun State, southwest Nigeria. Annals of Tropical Medicine and Parasitology, 82, 181–184.
• Robinson S.C. 1962. Trichomonal vaginitis resistant to metronidazole. Canadian Medical Association Journal, 86, 665.
• Saksirisampant W., Nuchprayoon S., Wiwanitkit V., Yenthakam S., Ampavasiri A. 2003. Intestinal parasitic infestations among children in an orphanage in Pathum Thani province. Journal of the Medical Association of Thailand, 86, 263–270.
• Schwebke J.R., Burgess D. 2004. Trichomoniasis. Clinical Microbiology Reviews, 17, 794–803. DOI: 10.1128/CMR.17.4.794-803.2004.
• Shaio M.F., Lo H.S., Huang S.W. 1981. Trichomonas hominis: isolation and axenic cultivation. Chinese Journal of Microbiology and Immunology, 14, 73–77 (In Chinese with English summary).
• Sheehan D.J., Hitchcock C.A., Sibley C.M. 1999. Current and emerging azole antifungal agents. Clinical Microbiology Reviews, 12, 40–79.
• Upcroft J.A, Campbell R.W., Benakli K., Upcroft P., Vanelle P. 1999. Efficacy of new 5-nitroimidazoles against metronidazole-susceptible and — resistant Giardia, Trichomonas, and Entamoeba spp. Antimicrobial Agents and Chemotherapy, 43, 73–76.
• Wassmann C., Bruchhaus I. 2000. Superoxide dismutase reduces susceptibility to metronidazole of the pathogenic protozoan Entamoeba histolytica under microaerophilic but not under anaerobic conditions. Archives of Biochemistry and Biophysics, 376, 236–238. DOI: 10.1006/abbi.2000.1707.
• Wassmann C., Hellberg A., Tannich E., Bruchhaus I. 1999. Metronidazole resistance in the protozoan parasite Entamoeba histolytica is associated with increased expression of ironcontaining superoxide dismutase and peroxiredoxin and decreased expression of ferredoxin 1 and flavin reductase. Journal of Biological Chemistry, 274, 26051–26056. DOI: 10.1074/jbc.274.37.26051.
• Yang C.R., Meng Z.D., Wang X., Li Y.L., Zhang Y.X., Zhao Q.P. 1990. Diarrhoea surveillance in children aged under 5 years in a rural area of Hebei Province, China. Journal of Diarrhoeal Diseases Research, 8, 155–159.